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Antihemophilic globulin (AHG; Factor VIII) activity has been re- 
ported to  deteriorate rapidly in blood stored a t  + 1°C t o  6°C [4, 81. 
Because of this, Factor VIII-rich fibrinogen (Fraction I of COHN et 
al. [3]), is prepared from fresh blood and processing to  the frozen 
state is completed within 24 h following donation. On the other hand, 
BRINKHOUS et al. [2] found 37% of the activity remaining after 
21 days. BOWIE, THOMPSON and OWEN [l] found that  one-half the 
normal level of Factor VIII  activity was still present after 21 days 
of storage at 4°C. I n  this communication we show tha t  clinically 
effective amounts of Factor VIII  activity are also present in certain 
lots of dried fibrinogen (human) prepared from outdated citrated 
whole blood (21 days or older). 
Eighteen lots of human fibrinogen were assayed in vitro for their 
Factor VIII  content by determining their ability t o  shorten the 
prolonged clotting time of recalcified hemophilic plasma, using a 
method by  NILSSON, BLOMBACK and VON FRANCKEN [5 ] .  The assay 
system consisted of 0.1 ml hemophilic plasma, 0.1 ml of a reference 
standard Factor VIII  preparation (or fibrinogen in various dilutions) 
and 0.1 ml of 0.03 M CaCl,. The reference standard Factor VIII  
preparation was a lot of dried antihemophilic globulin (M.D.H. No.83). 
Fifty milligram (dry weight) aliquots of this reference material and 
of the test lots of dried fibrinogen were reconstituted in 5 ml saline 
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and assayed at  dilutions in saline of 1/10, 1/20, 1/50 and 1/100. The 
clotting time of the recalcified plasma at  37°C was determined for 
each dilution of fibrinogen and of the standard and was plotted on 
log-log paper (clotting time versus dilution). Straight parallel lines 
were obtained. The antihemophilic potency of the test fibrinogen 
lots was established by comparing the dilutions of the unknown and 
the reference Factor VIII preparation which gave identical plasma 
clotting times. The Factor VIII standard was assigned a “potency” 
value of 100, based on the following: One-hundred milligrams of 
standard Factor VIII protein was found to contain the antihemo- 
philic factor activity equivalent to 3.8 ml of fresh normal human 
plasma. The relative potencies of the various lots of fibrinogen are 
given in Table I. 
TABLE I 
Factor V I I I  Activity of Fibrinogen Prepared from Outdated Blood 
~ ~ ~ ~ 
Lot No. % Standard* Lot No. % Standard* Lot No. % Standard. 
1 50 8 89 15 85 
2 178 9 15 16 162 
3 154 10 32 17 86 
4 51 11 29 18 35 
5 67 12 10 
7 92 14 90 
6 86 13 25 Average 75 
units/mg Protein fibrinogen lots 
units/mg Protein Factor VIII standard 
* =  x 100 
It can be seen from Table I that 12 of the 18 lots of fibrinogen 
prepared from outdated blood had 50% or more of the activity of 
the Factor VIII reference standard which was made from fresh blood. 
Three lots [2, 3, 161 had considerably greater activity than the re- 
ference and three lots [7, 8, 141 had activities close to that of the 
reference. The average activity of the 18 lots was 75% of the re- 
ference standard. Pxoduction lots of antihemophilic globulin pre- 
pared in the same manner as fibrinogen but from fresh plasma have 
an average activity equivalent to the standard. 
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I n  vitro assays for antihemophilic activity based on the correction 
of the prolonged recalcified clotting time of hemophilic plasma may 
not necessarily reflect the clinical value of the product following 
administration t o  hemophiliacs. Therefore, the clinical value of three 
of these fibrinogen preparations (lot Nos. 1, 8 and 16) was evaluated 
in classical hemophiliacs admitted to  The University of Michigan 
Hospital, Ann Arbor, Mich. The prothrombin activation rate [6] 
was used to  measure Factor VIII activity in vivo using plasma 
samples recovered following intravenous administration. All three lots 
produced in vivo activity that  was 50-75y0 of that produced by 
administering an equal amount of either a) a routine antihemophilic 
globulin product, or b) a commercially available fibrinogen con- 
taining antihemophilic globulin, or c) the equivalent volume of fresh 
plasma [7]. These clinical data further confirm that some of the 
fibrinogen lots routinely prepared by our laboratories from outdated 
blood do have significant antihemophilic activity. 
The large variation from lot t o  lot in the Factor VIII activity of 
our fibrinogen product may be attributed in part to the variable 
conditions of storage of the whole blood and the Fraction I subse- 
quently separated from it. In  some cases, the Fraction I paste that  
had been used in producing the lots of fibrinogen cited above had 
been stored for extended periods at -20°C. When the Fraction I paste 
is suspended in final buffer, processing is rapid until the product is 
frozen prior to  drying in vacuo. The holding period prior t o  drying 
ia purposely kept short. Undoubtedly, other as yet unrecognized 
factors may influence the final antihemophilic potency of these 
routine lots of fibrinogen. 
Factor VIII-rich fibrinogen (antihemophilic globulin-human) is in 
short supply and is quite expensive. It would appear from our data 
tha t  about two-thirds of the fibrinogen preparations made by the 
Michigan Department of Health from outdated blood contain 50% 
or more of the Factor VIII activity of our reference lot made from 
fresh blood. The more potent of these lots may be considered for use 
in bleeding episodes in hemophiliacs when Factor VIII concentrates 
from fresh plasma are not available. Finally, it seems t o  us that other 
large stockpiles of Fraction I (fibrinogen) made from outdated blood 
should be screened and studied in an attempt t o  determine their 
value as potential sources of satisfactory Factor VIII preparations 
for the treatment of bleeding episodes in hemophiliacs. 
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